This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2017 Oct 12;377(15):1409-1412.

doi: 10.1056/NEJMp1709968.

First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication

Steven Lemery¹, Patricia Keegan¹, Richard Pazdur¹

Affiliations

Affiliation

¹ From the Office of Hematology and Oncology Products (S.L., P.K.) and the Oncology Center of Excellence (R.P.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

PMID: 29020592
DOI: 10.1056/NEJMp1709968

First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication

Steven Lemery et al. N Engl J Med. 2017.

. 2017 Oct 12;377(15):1409-1412.

doi: 10.1056/NEJMp1709968.

Authors

Steven Lemery¹, Patricia Keegan¹, Richard Pazdur¹

Affiliation

¹ From the Office of Hematology and Oncology Products (S.L., P.K.) and the Oncology Center of Excellence (R.P.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

PMID: 29020592
DOI: 10.1056/NEJMp1709968

No abstract available

PubMed Disclaimer

Similar articles

Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
Prasad V, Kaestner V, Mailankody S. Prasad V, et al. JAMA Oncol. 2018 Feb 1;4(2):157-158. doi: 10.1001/jamaoncol.2017.4182. JAMA Oncol. 2018. PMID: 29285544 No abstract available.
Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
Hong YD, Enewold L, Halpern MT, Zeruto C, Mariotto AB. Hong YD, et al. Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5745. doi: 10.1002/pds.5745. Epub 2023 Dec 29. Pharmacoepidemiol Drug Saf. 2024. PMID: 38156547
First Tissue-Agnostic Drug Approval Issued.
[No authors listed] [No authors listed] Cancer Discov. 2017 Jul;7(7):656. doi: 10.1158/2159-8290.CD-NB2017-078. Epub 2017 Jun 5. Cancer Discov. 2017. PMID: 28583911
MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer.
Aguiar PN Jr, Tadokoro H, Forones NM, de Mello RA. Aguiar PN Jr, et al. Immunotherapy. 2015;7(11):1133-4. doi: 10.2217/imt.15.84. Epub 2015 Nov 16. Immunotherapy. 2015. PMID: 26568256 Review. No abstract available.
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Boyiadzis MM, et al. J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x. J Immunother Cancer. 2018. PMID: 29754585 Free PMC article. Review.

See all similar articles

Cited by

Deciphering the Tumor Microenvironment in Prostate Cancer: A Focus on the Stromal Component.
Pakula H, Pederzoli F, Fanelli GN, Nuzzo PV, Rodrigues S, Loda M. Pakula H, et al. Cancers (Basel). 2024 Oct 31;16(21):3685. doi: 10.3390/cancers16213685. Cancers (Basel). 2024. PMID: 39518123 Free PMC article. Review.
A comprehensive investigation of associations between cell death pathways and molecular and clinical features in pan-cancer.
He Y, Wang X. He Y, et al. Clin Transl Oncol. 2024 Nov 2. doi: 10.1007/s12094-024-03769-x. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39487950
Assessing the Prognostic Value of 13 Inflammation-Based Scores in Patients with Unresectable or Advanced Biliary Tract Carcinoma After Immunotherapy.
Wang F, Jiang C, He W, Li H, Guo GF, Xu L. Wang F, et al. Immunotargets Ther. 2024 Oct 16;13:541-557. doi: 10.2147/ITT.S471502. eCollection 2024. Immunotargets Ther. 2024. PMID: 39431245 Free PMC article.
Prognostic biomarkers for immunotherapy in esophageal cancer.
Tong X, Jin M, Wang L, Zhang D, Yin Y, Shen Q. Tong X, et al. Front Immunol. 2024 Sep 30;15:1420399. doi: 10.3389/fimmu.2024.1420399. eCollection 2024. Front Immunol. 2024. PMID: 39403382 Free PMC article. Review.
A case of MSI-high pancreatic body-tail cancer successfully treated with radical resection after pembrolizumab.
Ito M, Watanabe T, Oga Y, Matsumoto S, Kimura N, Nagamori M, Tanaka H, Shibuya K, Yoshioka I, Fujii T. Ito M, et al. Clin J Gastroenterol. 2024 Oct 14. doi: 10.1007/s12328-024-02043-5. Online ahead of print. Clin J Gastroenterol. 2024. PMID: 39402396

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program